Perioperative α-receptor blockade in phaeochromocytoma surgery: an observational case series

Br J Anaesth. 2017 Feb;118(2):182-189. doi: 10.1093/bja/aew392.

Abstract

Background: Mortality associated with surgery for phaeochromocytoma has dramatically decreased over the last decades. Many factors contributed to the dramatic decline of the mortality rate, and the influence of an α-receptor blockade is unclear and has never been tested in a randomized trial. We evaluated intraoperative haemodynamic conditions and the incidence of complications in patients with and without α-receptor blockade undergoing surgery for catecholamine producing tumours.

Methods: Haemodynamic conditions and perioperative complications were assessed in 110 patients with (B) and 166 without (N) α-receptor blockade. Data were analysed as a consecutive case series of 303 cases and subsequently via propensity score matching, and presented as mean and confidence interval (CI).

Results: No difference in maximal intraoperative systolic arterial pressures (B = 178 mm Hg (CI 169-187) vs N = 185 mm Hg (CI 177-193; P = 0.2542) and hypertensive episodes above 250 mm Hg were found (P = 0.7474) for the closed case series. No major complications occurred. Propensity score matching (75 pairs) revealed a significant difference of 17 mm Hg in maximal intraoperative systolic bp for these selected pairs (P = 0.024).

Conclusions: Only a slight difference in mean maximal systolic arterial pressure was detected between patients with or without an α-receptor blockade. There was no difference in the incidence of excessive hypertensive episodes between groups and no major complications occurred. The basis for the general recommendation of perioperative α- receptor blockade for phaeochromocytoma surgery demands further study.

Keywords: doxazosin; paraganglioma; phaeochromocytoma; phenoxybenzamine.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Adrenal Gland Neoplasms / physiopathology
  • Adrenal Gland Neoplasms / surgery*
  • Adrenergic alpha-Antagonists / adverse effects
  • Adrenergic alpha-Antagonists / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Hemodynamics / drug effects
  • Humans
  • Male
  • Middle Aged
  • Pheochromocytoma / physiopathology
  • Pheochromocytoma / surgery*
  • Propensity Score
  • Young Adult

Substances

  • Adrenergic alpha-Antagonists